Table 1.
Clinical Characteristics of Study Population
| Training Set | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Healthy | Benign | PDAC | ||||||||
| Source | Age Range (Median) | Gender | Source | Age Range (Median) | Gender | Dx | Source | Age Range (Median) | Gender | Stage |
| UPCI n = 45 |
24–69 (53) | M = 36 F = 9 |
UAB n = 57 |
32–83 (55) | M = 23 F = 34 |
C = 31 P = 17 O = 9 |
NUH n = 57 |
49–91 (73) |
M = 29 F = 28 |
I = 2 II = 18 III = 1 IV = 34 U = 2 |
| FCCC n = 35 |
39–87 (66) | M = 1 F = 34 |
NUH n = 17 |
23–83 (66) | M = 6 F = 11 |
C = 1 P = 8 O = 8 |
UAB n = 49 |
42–89 (68) | M = 20 F = 29 |
I = 1 II = 3 III = 2 IV = 3 U = 40 |
| NUH n = 19 |
33–77 (55) | M = 6 F = 13 |
SKCC n = 36 |
45–83 (64) | M = 17 F = 19 |
I = 0 II = 12 III = 5 IV = 6 U = 13 |
||||
| GOG n = 8 |
18–61 (44) | M = 0 F = 8 |
UPCI n = 18 |
49–87 (70) | M = 9 F = 9 |
I = 1 II = 0 III = 8 IV = 1 U = 8 |
||||
| Total Healthy n = 107 |
18–87 (58) | M = 43 F = 64 |
Total Benign n = 74 |
23–83 (56) | M = 29 F = 45 |
C = 32 P = 25 O = 17 |
Total PDAC n = 160 |
42–91 (69) | M = 75 F = 85 |
I = 4 II = 33 III = 16 IV = 44 U = 63 |
|
Validation Set | ||||||||||
| Healthy | Benign | PDAC | ||||||||
| Source | Age Range (Median) | Gender | Source | Age Range (Median) | Gender | Dx | Source | Age Range (Median) | Gender | Stage |
| UPCI n = 46 |
20–76 (51) | M = 34 F = 12 |
UAB n = 54 |
43–85 (57) | M = 35 F = 19 |
C = 16 P = 19 O = 19 |
UAB n = 55 |
44–91 (67) | M = 36 F = 29 |
I = 0 II = 6 III = 4 IV = 6 U = 39 |
| FCCC n = 37 |
37–84 (65) | M = 6 F = 31 |
NUH n = 16 |
35–86 (75) | M = 7 F = 9 |
C = 2 P = 8 O = 6 |
SKCC n = 52 |
45–83 (65) | M = 22 F = 30 |
I = 0 II = 16 III = 10 IV = 2 U = 24 |
| NUH n = 27 |
34–87 (54) | M = 5 F = 22 |
NUH n = 46 |
42–92 (74) | M = 22 F = 24 |
I = 3 II = 14 III = 0 IV = 29 U = 0 |
||||
| GOG n = 10 |
39–56 (51) | M = 0 F = 10 |
UPCI n = 20 |
29–82 (64) | M = 8 F = 12 |
I = 1 II = 1 III = 6 IV = 4 U = 8 |
||||
| Total Healthy n = 120 |
20–87 (54) | M = 45 F = 75 |
Total Benign n = 70 |
35–86 (66) | M = 42 F = 28 |
C = 18 P = 27 O = 25 |
Total PDAC n = 173 |
29–92 (68) | M = 88 F = 95 |
I = 4 II = 37 III = 20 IV = 41 U = 71 |
|
Non-PDAC Cancer Set | ||||||||||
| Colon | Lung | Breast | ||||||||
| Source | Age Range (Median) | Gender | Source | Age Range (Median) | Gender | Dx | Source | Age Range (Median) | Gender | Dx |
| UPCI n = 33 |
47–89 (64.5) | M = 18 F = 15 |
UPCI n = 62 |
46–99 (68) | M = 30 F = 32 |
Ad = 33 Sq = 29 |
Duke n = 108 |
52–82 (63) | F = 108 | IDC = 108 |
Sources: UPCI – University of Pittsburgh Cancer Institute; FCCC – Fox Chase Cancer Center; NUH – NorthShore University HealthSystems; GOG – Gynecological Oncology Group; UAB – University of Alabama-Birmingham; SKCC – Sloan-Kettering Cancer Center; Duke – Duke University; Benign Dx: C – Benign Cyst; P – Pancreatitis;O – Other benign neoplasm; PDAC Dx: U – stage unknown; Ad – adenocarcinoma; Sq – squamous cell carcinoma; IDC – invasive ductal carcinoma